Advertisement

Adjuvant Chemotherapy of Post-Surgical Minimal Residual Bronchial Carcinomas

  • K. Karrer
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)

Abstract

Primary cancer of the lung was rare and always fatal before the early 1930s. It is now common and selectively curable [35]. Bronchogenic carcinomas today represent a great and growing problem. In 1914 the total number of deaths in the United States attributed to lung cancer was 317. In 1930 the figure was 2357, in 1940 it was 7121, in 1950 it was 18,313, and in 1960 deaths attributed to this cause numbered 36,420. In 1965 the total number of deaths from lung cancer was 53,000. It is estimated that more than 80,000 deaths per annum will occur by 1980 in the United States. Although female incidence of lung and bronchial cancer is considerably lower than male incidence, it has been increasing almost as rapidly as male incidence during the past 20 years [3]. Similarly, increasing figures are also reported from many other countries [7, 42, 43].

Keywords

Adjuvant Chemotherapy Life Table Chemotherapy Group Bronchogenic Carcinoma Bronchial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Adelberger, L., Wörn, H.: Erfahrungen und Aussichten der kombinierten chirurgisch-zytostatischen Behandlung des Bronchialkarzinoms. Mitteilungsdienst der Ges. z. Bekämpf. d. Krebskrankh. 2, 521 (1962).Google Scholar
  2. 2.
    Arnal, M. L., Dold, U., Ehlers, C. Th., Gögler, E., Hamperl, H., Karrer, K., Oberhofer, G., Ott, G., Pascher, W., Proppe, A., Scheibe, O., Schmolling, E., Spiessl, B., Thurmayer, R., Wildner, E. P.: Zur Klassifizierung der Geschwulstkrankheiten. Der „gesicherte“ TNM-Schlüssel (Erweiterungsvorschlag zu den „General Rules” der UICC). Methods Inf. Med. 6, 70 (1967).Google Scholar
  3. 3.
    Axtell, L. M., Asire, A. J., Myers, M. H.: Cancer patient survival 5. DHEW Publication no. (NIH) 77-992. Washington, D. C.: U.S. Government Printing Office 1976.Google Scholar
  4. 4.
    Brunner, K. W., Marthaler, Th., Müller, W.: Unfavourable effects of long-term adjuvant chemotherapy with Endoxan in radically operated bronchogenic carcinoma. Eur. J. Cancer 7, 285 (1971).PubMedCrossRefGoogle Scholar
  5. 5.
    Buyze, E. A. C., Nelemans, F. A.: A study of postoperative cytostatic medication in patients with operable carcinoma of the lung. Arzneim. Forsch. 23, 860 (1973).Google Scholar
  6. 6.
    Crosbie, W. A., Candar, H. H., Belcher, J. R.: A control trial of vinblastine sulfate in the treatment of carcinoma of the lung. Br. J. Dis. Chest 60, 28–35 (1966).PubMedCrossRefGoogle Scholar
  7. 7.
    Cutler, S. J., Young, J. L.: Third National Cancer Survey: Indicence Data. Washington, D. C.: U.S. Government Printing Office 1975.Google Scholar
  8. 8.
    Denk, W., Karrer, K.: Modellversuch einer Rezidivprophylaxe des Karzinoms. Wiener Klin. Wochenschr. 67, 986 (1955).Google Scholar
  9. 9.
    Feinstein, A. R.: Symptomatic patterns, biologic behavior and prognosis in cancer of the lung. Ann. Intern. Med. 61, 27 (1964).PubMedGoogle Scholar
  10. 10.
    Fisher, R. A.: Fishers exakter Vierfeldertest. In: Statistische Auswertungsmethoden. Sachs, L. (ed.), p. 365. Berlin, Heidelberg, New York: Springer 1969.Google Scholar
  11. 11.
    Friedl, H. P., Karrer, K., Kühböck, J.: The relation of tumour size to the results of chemotherapy in malignant tumours. Eur. J. Clin. Biol. Res. 16, 268–272 (1971).Google Scholar
  12. 12.
    Friedl, H. P., Karrer, K.: Adjuvant Chemotherapy on Metastasizing Experimental Tumors. Proc. VIIth Int. Congr. Chemotherapy, Prague: Advances in Antimicrobial and Antineoplastic Chemotherapy. Hejzlar, M. (ed.), pp. 285-286. München, Berlin, Wien: Urban & Schwarzenberg 1972.Google Scholar
  13. 13.
    Higgins, G. A. (Jr.): Use of Chemotherapy as an Adjuvant to Surgery for Bronchogenic Carcinoma. Cancer 30, 1383–1387 (1972).PubMedCrossRefGoogle Scholar
  14. 14.
    Humphreys, S. R., DeWys, W. D., Karrer, K.: A model System for the Selection of Drugs for Chemotherapy of Metastasis. Proc. 5th Int. Congr. Chemotherapy, Vienna, June 26–July 1, B 9/17 1967.Google Scholar
  15. 15.
    Humphreys, S. R., Karrer, K.: Relationship of dose schedules to the effectiveness of adjuvant chemotherapy. Cancer Chemother. Rep. 54, 379–392 (1970).PubMedGoogle Scholar
  16. 16.
    Karrer, K., Humphreys, S. R., Goldin, A.: Relationship of drug toxicity to chemotherapeutic effektiveness. Antimicrob. Agents Chemother. 539-543 (1965).Google Scholar
  17. 17.
    Karrer, K.: Experimentelle Studien zum Problem der Tumormetastasierung I bis III. Klin. Med. 20, 313 (1965).Google Scholar
  18. 18.
    Karrer, K., Humphreys, S. R., Goldin, A.: Ein neues experimentelles Modell zum Studium der Beeinflußbarkeit der Metastasierung maligner Tumoren. Krebsforsch. Krebsbek. 6, 166–169 (1967).Google Scholar
  19. 19.
    Karrer, K., Humphreys, S. R., Goldin, A.: An experimental model for studying factors which influence metastases of malignant tumours. Int. J. Cancer 2, 213–223 (1967).PubMedCrossRefGoogle Scholar
  20. 20.
    Karrer, K., Humphreys, S. R.: Continuous and limited Courses of Cyclophosphamide (NSC-26271) in Mice with pulmonary Metastasis after Surgery. Cancer Treat. Rep. 51, 439–449 (1967).Google Scholar
  21. 21.
    Karrer, K., Denck, H.: Weitere Vorschläge zur chemotherapeutischen Rezidivprophylaxe des Bronchuskarzinoms. Wiener Med. Wochenschr. 121, 112–120 (1971).Google Scholar
  22. 22.
    Karrer, K.: Relations of dose schedules of adjuvant chemotherapy in experimental systems and in clinical trials. Poc. VIIth Int. Congr. Chemotherapy, Prague: Advances in Antimicrobial and Antineoplastic Chemotherapy. Hejzlar, M. (ed.), pp. 765-768. München, Berlin, Wien: Urban & Schwarzenberg 1972.Google Scholar
  23. 23.
    Karrer, K.: Surgical adjuvant therapy. Proceedings of the XIth International Cancer Congress, Florence 1974. Excerpta Medica Int. Congr. Series No. 353, 5, 68–73 (1974).Google Scholar
  24. 24.
    Karrer, K., Pridun, N., Denck, H., Sighart, H.: Polychemotherapie bei Patienten nach radikaler Operation wegen Bronchus-Karzinom. Österr. Z. Onkologie 3, 127–141 (1976).Google Scholar
  25. 25.
    Karrer, K., Pridun, N., Denck, H.: Chemotherapy as an adjuvant to surgery in lung cancer. Cancer Chemother. Pharmacol. (in press) (1978).Google Scholar
  26. 26.
    Katsuki, H., Shimada, K. et al.: Long-term intermittent adjuvant chemotherapy for primary, resected lung cancer. J. Thorac. and Cardiovasc. Surg. 70, 590 (1975).Google Scholar
  27. 27.
    Kreyberg, L., Libow, A. A., Uehlinger, E. A. W.: International histological classification of tumors. 1. Histological typing of lung tumors. Geneva: WHO 1967.Google Scholar
  28. 28.
    Legha, S. S., Muggia, F. M., Carter, S. K.: Adjuvant chemotherapy in lung cancer. Cancer 39, 1415–1424 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    Livingston, R. B.: Combined modality approaches in lung cancer. In: Adjuvant therapy of cancer. Salmon, S. E. (ed.), pp. 191-205. Amsterdam, Oxford, New York: North-Holland 1977.Google Scholar
  30. 30.
    Ludwig Lung Cancer Study Group: Search for the possible Role of “Immunotherapy” in operable Bronchial non-small Cell Carcinoma (Stage I and II): A Phase I Study with Corynebacterium parvum Intrapleurally. Cancer Immunol. Immunother. (in press) (1978).Google Scholar
  31. 31.
    Mayo, J. A., Laster, W. R. (Jr.), Andrews, C. M., Schabel, F. M. (Jr.): Success and failure in the treatment of solid tumors — III “Cure” of metastatic Lewis lung carcinoma with methyl-CCNU and surgery-chemotherapy. Cancer Treat. Rep. 56, 183–195 (1972).Google Scholar
  32. 32.
    Miller, A. B.: (A medical Research Council Working Party) Study of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br. Med. J. 1972/II, 421-428.Google Scholar
  33. 33.
    Mountain, C. F.: The surgeon’s viewpoint on collaborative research on lung cancer. Cancer Treat. Rep. 4, 307–309 (1973).Google Scholar
  34. 34.
    Overholt, R. H., Oliynyk, Cady, B.: The current status of primary cancer of the lung..Google Scholar
  35. 35.
    Overholt, R. H., Neptune, W. B., Ashraf, M. M.: Primary cancer of the lung. Ann. Thorac. Surg. 20, 511–519 (1975).PubMedCrossRefGoogle Scholar
  36. 36.
    Pavlov, A., Pirogov, A., Trachtenberg, A., Volkova, M., Maximov, T., Matveeva, T.: Results of combination treatment of lung cancer patients: surgery plus radiotherapy and surgery plus chemotherapy. Cancer Treat. Rep. 4, 133 (1973).Google Scholar
  37. 37.
    Perloff, M., Holland, J. F.: Surgical adjuvant chemotherapy. Ann. Rev. Med. 28, 475–488 (1977).PubMedCrossRefGoogle Scholar
  38. 38.
    Pfeiffer, K. M., Middendorp, U. G., Marthaler, Th.: Cytostatische Rezidivprophylaxe operierter maligner Tumoren. Schweiz. Med. Wochenschr. 96, 903 (1966).PubMedGoogle Scholar
  39. 39.
    Poulsen, O.: Prae-und postoperative cytostatische Behandlung von Lungencarcinomen mit Cyclophosphamid. Arzneim. Forsch. 11, 238 (1961).Google Scholar
  40. 40.
    Scadding, J. G.: Study of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br. Med. J. 1971/II, 421.Google Scholar
  41. 41.
    Schabel, F. M., (Jr.): Experimental basis for adjuvant chemotherapy. In: Adjuvant therapy of cancer. Salmon, S. E. (ed.), pp. 3-14. Amsterdam, Oxford, New York: North-Holland 1977.Google Scholar
  42. 42.
    Schottenfeld, D., Houde, R. W.: The changing pattern of cancer morbidity and mortality and its implications. Med. Clin. North Am. 50, 613 (1966).PubMedGoogle Scholar
  43. 43.
    Segi, M., Kurihara, M.: Cancer mortality for selected sites in 24 countries. No. 6 (1966/1967), Jpn. Cancer Soc. 110 (1972).Google Scholar
  44. 44.
    Shields, T. W., Robinette, C. D., Keehn, R. J.: Bronchial carcinoma treated by adjuvant cancer chemotherapy. Arch. Surg. 109, 329–333 (1974).PubMedCrossRefGoogle Scholar
  45. 45.
    Slack, N. H.: Bronchogenic carcinoma: nitrogen mustard as a surgical adjuvant and factors influencing survival. Cancer 25, 987 (1970).PubMedCrossRefGoogle Scholar
  46. 46.
    Vincent, R. G., Takita, H., Lane, W. W., Gutierrez, A. C., Pickren, J. W.: Surgical therapy of lung cancer. J. Thorac. Cardiovasc. Surg. 71, 581–591 (1976).PubMedGoogle Scholar
  47. 47.
    Wilcoxon, F., Mann, H. B., Whitney, D. R.: U-Test. In: Statistische Auswertungsmethoden. Sachs, L. (ed.), p. 293. Berlin, Heidelberg, New York: Springer 1969.Google Scholar
  48. 48.
    Wingfield, H. V.: Combined surgery and chemotherapy for carcinoma of the bronchus. Lancet 1970/I, 470-471.Google Scholar
  49. 49.
    Wurnig, P., Scheuba, G., Karrer, K.: Vorläufige Ergebnisse der chemotherapeutischen Rezidivprophylaxe mit Mitomen beim operierten Bronchuscarcinom. Acta Union Internationale Contre le Cancer, XVI, 935-936, 1960.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • K. Karrer

There are no affiliations available

Personalised recommendations